论文部分内容阅读
目的:探讨VEGF-C、VEGFR-3、CD105及CD68蛋白在食管鳞状细胞癌(ESCC)组织中的表达及其与血管和淋巴管转移的关系.方法:应用免疫组化SP法检测50例ESCC、19例癌旁不典型增生组织及50例正常食管黏膜组织中VEGF-C、VEGFR-3、CD105和CD68蛋白的表达.分析这些蛋白表达与ESCC临床生物学行为的关系.结果:ESCC、癌旁不典型增生组织及正常黏膜组织中VEGF-C、VEGFR-3、CD105和CD68蛋白的阳性表达率依次降低(VEGF-C:82.0%,47.4%,26.0%;VEGFR-3:72.0%,36.8%,18.0%;CD105:30.53±7.42,0,0;CD68:50.89±10.36,14.10±3.59,11.30士3.72),组间比较差异均有统计学意义(P<0.05).结论:联合检测VEGF-C、VEGFR-3、CD105和CD68蛋白可望成为食管鳞癌早期诊断、判断预后及预测淋巴管及血管转移的分子指标之一,为临床的免疫治疗和抗淋巴管及血管转移治疗提供客观、科学、可靠的依据.
Objective: To investigate the expression of VEGF-C, VEGFR-3, CD105 and CD68 in esophageal squamous cell carcinoma (ESCC) and their relationship with vascular and lymphatic metastasis.Methods: Immunohistochemical SP method was used to detect 50 cases ESCC, the expression of VEGF-C, VEGFR-3, CD105 and CD68 in 19 cases of paraneoplastic atypical hyperplasia tissues and 50 cases of normal esophageal mucosa tissues.Results: The relationship between ESCC, The positive expression rates of VEGF-C, VEGFR-3, CD105 and CD68 in atypical hyperplasia tissues and normal mucosa tissues were significantly lower than those in normal tissues (82.0%, 47.4%, 26.0%, VEGFR- 36.8%, 18.0%; CD105: 30.53 ± 7.42,0,0; CD68: 50.89 ± 10.36,14.10 ± 3.59,11.30 ± 3.72), there were significant differences between the two groups (P <0.05) .Conclusion: VEGF-C, VEGFR-3, CD105 and CD68 proteins are expected to be one of the molecular markers for the early diagnosis, prognosis and prediction of lymphatic vessel and vascular metastasis of esophageal squamous cell carcinoma, providing clinical immunotherapy and anti-lymphatic and vascular transfer therapy Objective, scientific, reliable basis.